Potential antagonism of tubulin-binding anticancer agents in combination therapies

Clinical Cancer Research

Volumn 11, Issue 7, 2005, Pages 2720-2726

  Taraboletti, Giulia ^a   Micheletti, Gianluca ^a   Dossi, Romina ^a   Borsotti, Patrizia ^a   Martinelli, Michele ^a   Fiordaliso, Fabio ^b   Ryan, Anderson J ^c   Giavazzi, Raffaella ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; TUBULIN; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOSKELETON; DRUG ANTAGONISM; DRUG PROTEIN BINDING; DRUG SENSITIVITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MICROTUBULE; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROTEIN STABILITY; TUMOR NECROSIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; COLCHICINE; CYTOSKELETON; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NECROSIS; ORGANOPHOSPHORUS COMPOUNDS; PACLITAXEL; PROTEIN BINDING; TAXOIDS; TUBULIN; UMBILICAL VEINS; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 17644395253     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1616     Document Type: Article

References (28)

1. Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999;80 Suppl 1:57-64.
2. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
3. Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 2000; 10:435-42.
4. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
5. Hoffman JA, Giraudo E, Singh M, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 2003;4:383-91.
6. Rafii S, Avecilla ST, Jin DK. Tumor vasculature address book: identification of stage-specific tumor vessel zip codes by phage display. Cancer Cell 2003;4:331-3.
7. Taraboletti G, Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol 2001;1:378-84.
8. Micheletti G, Poli M, Borsotti P, et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003;63:1534-7.
9. Blakey DC, Westwood FR, Walter M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8: 1974-83.
10. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62:7247-53.
11. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53:164-71.
12. McCarty MF, Takeda A, Stoeltzing O, et al. ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer. Br J Cancer 2004;90:705-11.
13. Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;54:1512-7.
14. Siemann DW, Horsman MR. Enhancement of radiation therapy by vascular targeting agents. Curr Opin Investig Drugs 2002;3:1660-5.
15. Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003;57:1047-55.
16. Taraboletti G, Micheletti G, Rieppi M, et al. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 2002;8:1182-8.
17. Bayless KJ, Davis GE. Microtubule depolymerization rapidly collapses capillary tube networks in vitro and angiogenic vessels in vivo through the small GTPase Rho. J Biol Chem 2004;279:11686-95. Epub 2003 Dec 29.
18. Krendel M, Zenke FT, Bokoch GM. Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. Nat Cell Biol 2002;4:294-301.
19. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99: 2060-9.
20. Eiseman JL, Eddington ND, Leslie J, et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 1994; 34:465-71.
21. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-90.
22. Dabydeen DA, Florence GJ, Paterson I, Hamel E. A quantitative evaluation of the effects of inhibitors of tubulin assembly on polymerization induced by discodermolide, epothilone B, and paclitaxel. Cancer Chemother Pharmacol 2004; 22:22
23. Giannakakou P, Villalba L, Li H, Poruchynsky M, Fojo T. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int J Cancer 1998;75:57-63.
24. Garcia P, Braguer D, Carles G, Briand C. Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses. Anticancer Drugs 1995;6:533-44.
25. Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999;10: 947-59.
26. Jordan MA, Wilson L. Microtubules as a targetfor anticancer drugs. Nat Rev Cancer 2004;4:253-65.
27. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99:1-6.
28. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res 2003;63:1144-7.